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An immunohistochemical study using 2 antihuman 
melanoma monoclonal antibodies designated as MoAb 
225.288 and MoAb 653.408 was carried out on various 
human skin tumors, including malignant melanoma as 
well as on normal and fetal tissues by indirect immuno-
fluorescence technique. Specific immunofluorescence 
was observed not only in malignant melanoma cells but 
also in cells of pigmented nevi, basal cell epithelioma, 
normal hair follicles, and some fetal tissues. Both mono-
clonal antibodies were revealed to be able to recognize 
the common antigenic determinant shared by several 
skin tumors, including malignant melanoma, and fetal 
tissues. Therefore, both monoclonal antibodies might 
recognize premature antigen of both melanocytic and 
keratiuocytic cell lineage. 
In the field of oncology, monoclonal antibody technology was 
introduced in expectation of finding tumor-, or cancer-specific 
antigens. In particular, active attention was focused on malig-
nant melanoma because it was believed to express strong tu-
mor-specific antigens. Subsequently, many monoclonal anti-
bodies against melanoma cells have been developed. However, 
it turned out that most of them recognized melanoma-associ-
ated antigen such as a common neuroectodermal antigen 
[1- 9]. 
In this study, the tissue reactivity of 2 monoclonal antihuman 
melanoma antibodies designated as MoAb 225.28S and MoAb 
653.40S was studied immunohistochemically. As a result of this 
study, we found that these monoclonal antibodies showed re-
activity to more various tissue specimens than ever reported 
(10-12]. 
MATERIALS AND METHODS 
Tissues 
A total of 23 specimens of human primary and metastatic malignant 
melanoma was used in this study. In addition , various pigmented nevi, 
several kinds of tumors of non-neural and neural tissue origin, and 
various parts of human normal and fetal tissue (9- 16 weeks of gesta-
tion) were also used. All tissues were freshly obtained at biopsy or 
operation. Human feta l tissues were obtained from artificial abortion 
materials. These tissues were immediately cut into halves; one was 
fixed in 10% forma lin solution for routine histopathologic exqmination 
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and the other was quickly frozen in normal hexane at - 8o· c and stored 
in a deep freezer until use for immunohistochemical studies. 
Monoclonal Antibodies to Human Malignant Melanoma 
Two monoclonal antibodies, designated as MoAb 225.288 and MoAb 
653.408, were used in this study and have been described in detail 
elsewhere [2,3]. The immunoglobulin subclass of each ant ibody was 
lgG2a (MoAb 225.288) and lgG1 (MoAb 653.408). An indirect inhibi-
tion binding assay suggests that both monoclonal antibodies recognize 
the same or closely associated antigenic determinants [13]. 
Indirect Immunofluorescence Technique 
Cryostat sections (4 I'm thick) were cut from frozen tissues and 
placed on albumin-coated glass slides. After air drying for 30 min, they 
were washed 3 times with cold phosphate-buffered saline (PBS) (pH 
7.2) for 30 min . and reacted with 225.288 or 653.408 monoclonal 
antibodies (both dilutions 1:40), for 30 min at room temperature in a 
moist chamber. After washing 3 times with cold PBS, fluorescein 
isothiocyanate (FITC) labeled sheep antimouse IgG 1 or IgG2a (Serotec, 
England, di lution 1:80) was applied to the slide for 30 min at room 
temperature in a moist chamber. Then the sections were thoroughly 
washed with cold PBS and mounted in buffered glycerol (pH 9.5) for 
observation by a Carl-Zeiss fluorescence microscope. Culture medium 
of myeloma cells was used for control study. 
RESULTS 
Melanotic Tumor 
As listed in Table I, both monoclonal antibodies reacted to a 
majority of malignant melanoma, both primary and metastatic 
lesions including amelanotic type. The specific immunofluores-
cence for both monoclonal antibodies was observed exclusively 
on the plasma membrane of the melanoma cells. The intensity 
of specific immunofluorescence was relatively heterogeneous 
depending on the area of the tumor. Some tumor cells lacked 
specific immunofluorescence. In malignant melanomas, the 
immunoreactivity of MoAb 225.28S was wider than that of 
MoAb 653.40S. The reactivity of both monoclonal antibodies 
suggests that there was no correlation with the clinical stage of 
melanoma, with the degree of invasiveness of primary lesion, 
with the amount of melanin, or with tumor cell morphology 
such as spindle-shaped or epithelioid-shaped. But in a case of 
malignant blue nevus, only epithelioid-shaped tumor cells were 
reacted and spindle-shaped tumor cells were not (Fig 1). In a 
case of lentigo maligna, both monoclonal antibodies reacted to 
some atypical melanocytes in the basal layer of the epidermis, 
but did not react to melanophages in the papillary layer of the 
dermis . 
Both monoclonal antibodies showed similar reactivity to all 
types of pigmented nevi except intradermal nevi . Exceptionally, 
MoAb 653.40S surpassed MoAb 225.28S in the immunoreactiv-
ity of intradermal nevi. Specific immunofluorescence was rel-
atively strong and evenly distributed on the cell surface of the 
nevus cells. However, neither common blue nevi nor cellular 
blue nevi showed reactivity to either of the monoclonal anti-
bodies. In some cases of intradermal nevus, hyperpigmented 
basal cells of the epidermis were revealed to react with both 
monoclonal antibodies. 
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TABLE I. Reactivity of MoAb 225.288 and MoAb 653.408 with 
melanomas and nevi 
Tissue 
Malignant melanoma: 
Primary melanoma 
Metastatic melanoma 
Malignant blue nevus 
P igmented nevi: 
Junctional nevi 
Compound nevi 
Intradermal nevi 
Blue nevi: 
Common blue nevi 
Cellula r blue nevi 
MoAb 225.288 
6/8 
13/15 
1/1 
2/2 
1/3 
6/20 
0/6 
0/2 
No. of positive cases/no. of total cases. 
MoAb 653.408 
2/3 
2/5 
1/1 
1/1 
1/1 
9/13 
0/3 
0/2 
FIG 1. Indirect immunofluorescence stain ing of malignant blue ne-
vus wit h the MoAb 225.288. The staining appears to be restricted to 
· the plasma membran e of epithelioid-shaped tumor cells. 
Normal Tissues and Various Tumors of Non-neural and 
Neural Origin 
Both monoclonal antibodies showed no reaction with normal 
skin , lymph nodes, and tonsils, including melanocytes in the 
epidermis; however, normal lower hair fo llicles showed positive 
staining (Fig 2). As shown in Table II, the reactivity of MoAb 
653.408 was greater than the reactivity of MoAb 225.288 in 
basal cell epithelioma (BCE) and squamous cell carcinoma 
(SCC) cases. Specific staining of them was observed on the 
plasma membrane of the tumor cells and the intensity of 
immunof1uorescence was as strong as that of nevus cells. 
In t he tumors of the nervous system, only schwannoma 
showed positive staining by MoAb 225.28S. 
Fetal Tissues 
MoAb 225.288 reacted with the skin of 8 out of 10 feti at 
from 9-16 weeks' gestation, and t he MoAb 653.408 reacted 
with all cases stained positively with MoAb 225.28S. The 
positive staining was observed on the plasma membrane of t he 
epidermal cells of the skin, including mela·nocytes (Fig 3). There 
was no positive staining in the periderm or immature mesen-
chymal cells in the dermis. In the fetal kidney of 16 weeks' 
gestation , only proximal tubules showed positive staining and 
glomerules and distal tubules did not react wit h either of the 
monoclonal antibodies (Fig 4). In the fetal rib bone of 9 weeks' 
gestation, chondroblasts were stained by bot h monoclonal an-
tibodies. Other fetal tissues, such as brain, liver, and intestine, 
did not show any positive staining. 
DISCUSSION 
There have been many reports concerning the production of 
monoclonal antibodies against human malignant melanoma [1-
9]. The majority of monoclonal antibodies to human malignant 
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FI G 2. Indirect immunofluorescence staining of a normal hair folli· 
cle with MoAb 653.40S. MoAb 653.40S stains only normal outer root 
sheath cells. 
TABLE II. Reactivity of both monoclonal antibodies to various tumors 
and normal human. tissu.es 
Tissue MoAb 225.288 MoAb 653.408 
Maligna nt t issues: 
BCE 5/12 9/10 
sec 2/8 4/6 
ML 0/3 0/2 
Tumors of nervous sys-
tern: 
Meningioma 0/6 0/1 
Glioma 0/1 NT 
Schwannoma 1/ 1 NT 
Ependymoma 0/1 0/1 
Glioblastoma 0/3 0/3 
Normal t issues: 
Epidermis 0/6 0/6 
Hair follicle 5/5 5/5 
Lymph node 0/3 0/3 
Tonsil 0/2 0/2 
Fetal tissues: 
Skin (9- 16 weeks) 8/10 9/9 
Kidney (16 weeks) 2/2 2/2 
Brain (9-16 weeks) 0/5 0/5 
Intestine (10- 11 weeks) 0/1 0/1 
Rib bone (9 weeks) 2/2 2/2 
Liver (10- 11 weeks) 0/3 0/3 
No. of positive cases/no. of total cases. NT == not tested. 
FIG 3. Indirect immunofluorescence staining of t he thigh skin of a 
16-week fetus. Specific staining is seen only on epidermal cells. 
melanoma reported previously seemed to be melanoma-associ-
ated rather than melanoma-specific because they have been 
shown to cross-react with various tumors other than melanoma 
[2- 9], pigmented nevi [1] , and even some normal human tissues 
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FIG 4. Indirect immunofluorescence staining of the kidney of a 16· 
week fetus. Specific staining is seen on t he epit helium of prox imal 
t ubules. 
[14]. The monoclonal antibodies used in this study are identical 
to those used by Wilson eta! and Natali et a l [10- 12] and the 
results obtained herein were s imilar to their reports. However 
several new findings a re reported concerning the immunoreac-
tivity of these monoclona l antibodies. 
Firstly, t he reactivity of these antibodies to malignant blue 
nevus has not been reported yet. It has been known that both 
common and cellula r blue nevi show no positive reaction to 
t hese monoclona l antibodies [12] . Malignant blue nevus origi-
nates from the common or cellular blue nevus . The refore, the 
expression of the antigen recognized by these antibodies seems 
to be assoc iated with t he mali gnant transformation of blue 
nevus cells. 
Secondly, alt hough the cross-reactivity of t hese antibodies to 
keratinocytic lineage such as BCE and SCC has been previously 
reported, the cross-reactivity to normal hair follicles and even 
epidermis of the fetal skin is not known [10- 12]. These findin gs 
show that the antigen detected by both monoclona l antibodies 
was expressed on malignant and premature keratinocytes. 
Thirdly, the cross-reactivity to fetal tisf>ues was previously 
reported by many investigato rs, however they mainly used a 
radioimmunoassay method fo r the demonstration of cross-
reactivity, and the precise distribution of t he antigen reactive 
to antimelanoma m onoclonal a n t ibodies in fetal t issues was 
not elucidated by immunohistochemical methods [15- 17] . This 
study is the first to demonst rate specific fluorescence in various 
fetal tissues. Therefore, t hese monoclonal antibodies seem 
to h ave a premature nature at least in both melanocyte a nd 
keratinocyte lineage bac kground rat her than a common neu-
roectodermal nature, because of the lack of reactivity to most 
neura l tumors a nd fetal brain tissues. Further sequential studies 
are necessary to clarify the nature of t he antigen detected bv 
these monoclonal a n t ibodies. 
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